SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Visible Genetics Inc.(VGIN)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Steve Lokness who wrote (177)4/8/1998 1:34:00 AM
From: Richard Haugland  Read Replies (1) of 337
 
Steve, Richard Harmon probably knows better that I do the competition. The companies like Applied Biosystems (part of Perkin Elmer) that do gel electrophoretic sequencing do NOT serve the same market. VGINF's sequencer has the advantage of being VERY fast compared to most technologies (because it is very thin). I suspect that their main competition for disease detection will be from companies that will do it on chips rather than by electrophoresis.

I believe that VGINF still has some connection with Amersham, who are also in the genome sequencing market as a much smaller competitor to ABI. There are suits and countersuits going on between Amersham + Molecular Dynamics versus ABI, but I don't expect that this will affect VGINF.

I don't know Oncometrics.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News